Advertisement
Screener

Arbutus Biopharma Corp (ABUS) Research and Development Expense

2.8 / 5 stars · 68/120 Roast Me

Arbutus Biopharma Corp Research and Development Expense

Arbutus Biopharma Corp (ABUS) reported Research and Development Expense of $2.90 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-12

CAD

Period endResearch and Development Expense 12 month
2012-12-3118.03M CAD
20-F · filed 2013-03-27
2011-12-3119.90M CAD
20-F · filed 2013-03-27
2010-12-3122.13M CAD
20-F · filed 2013-03-27
2009-12-3117.76M CAD
20-F · filed 2012-03-27

USD

Period endResearch and Development Expense 3 monthResearch and Development Expense 3 month as first filedResearch and Development Expense 6 monthResearch and Development Expense 6 month as first filedResearch and Development Expense 9 monthResearch and Development Expense 9 month as first filedResearch and Development Expense 12 monthResearch and Development Expense 12 month as first filed
2026-06-30$2.90M
10-Q · filed 2026-08-12
$7.02M
10-Q · filed 2026-08-12
$12.02M
derived: sum of 3 quarters · filed 2026-08-12
$17.80M
derived: sum of 4 quarters · filed 2026-08-12
2026-03-31$4.12M
10-Q · filed 2026-05-13
$9.13M
derived: sum of 2 quarters · filed 2026-05-13
$14.90M
derived: sum of 3 quarters · filed 2026-05-13
$20.40M
derived: sum of 4 quarters · filed 2026-08-12
2025-12-31$5.01M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23
$10.78M
derived: sum of 2 quarters · filed 2026-03-23
$16.28M
derived: sum of 3 quarters · filed 2026-08-12
$25.24M
10-K · filed 2026-03-23
2025-09-30$5.78M
10-Q · filed 2025-11-13
$11.28M
derived: sum of 2 quarters · filed 2026-08-12
$20.23M
10-Q · filed 2025-11-13
$29.05M
derived: sum of 4 quarters · filed 2026-08-12
2025-06-30$5.50M
10-Q · filed 2026-08-12
$14.46M
10-Q · filed 2026-08-12
$23.27M
derived: sum of 3 quarters · filed 2026-08-12
$37.54M
derived: sum of 4 quarters · filed 2026-08-12
2025-03-31$8.96M
10-Q · filed 2026-05-13
$17.77M
derived: sum of 2 quarters · filed 2026-05-13
$32.04M
derived: sum of 3 quarters · filed 2026-05-13
$47.59M
derived: sum of 4 quarters · filed 2026-05-13
2024-12-31$8.81M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23
$23.08M
derived: sum of 2 quarters · filed 2026-03-23
$38.63M
derived: sum of 3 quarters · filed 2026-03-23
$54.04M
10-K · filed 2026-03-23
2024-09-30$14.27M
10-Q · filed 2025-11-13
$29.82M
derived: sum of 2 quarters · filed 2025-11-13
$45.23M
10-Q · filed 2025-11-13
$62.79M
derived: sum of 4 quarters · filed 2025-11-13
2024-06-30$15.55M
10-Q · filed 2025-08-06
$30.95M
10-Q · filed 2025-08-06
$48.52M
derived: sum of 3 quarters · filed 2025-08-06
$68.69M
derived: sum of 4 quarters · filed 2025-08-06
2024-03-31$15.40M
10-Q · filed 2025-05-14
$32.97M
derived: sum of 2 quarters · filed 2025-05-14
$53.14M
derived: sum of 3 quarters · filed 2025-05-14
$70.83M
derived: sum of 4 quarters · filed 2025-05-14
2023-12-31$17.56M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27
$37.73M
derived: sum of 2 quarters · filed 2025-03-27
$55.42M
derived: sum of 3 quarters · filed 2025-03-27
$73.70M
10-K · filed 2025-03-27
2023-09-30$20.17M
10-Q · filed 2024-11-06
$37.86M
derived: sum of 2 quarters · filed 2024-11-06
$56.14M
10-Q · filed 2024-11-06
$79.08M
derived: sum of 4 quarters · filed 2024-11-06
2023-06-30$17.69M
10-Q · filed 2024-08-08
$35.97M
10-Q · filed 2024-08-08
$58.92M
derived: sum of 3 quarters · filed 2024-08-08
$78.97M
derived: sum of 4 quarters · filed 2024-08-08
2023-03-31$18.27M
10-Q · filed 2024-05-02
$41.22M
derived: sum of 2 quarters · filed 2024-05-02
$61.28M
derived: sum of 3 quarters · filed 2024-05-02
$84.22M
derived: sum of 4 quarters · filed 2024-05-02
2022-12-31$22.95M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05
$43.00M
derived: sum of 2 quarters · filed 2024-03-05
$65.95M
derived: sum of 3 quarters · filed 2024-03-05
$84.41M
10-K · filed 2024-03-05
2022-09-30$20.05M
10-Q · filed 2023-11-07
$43.00M
derived: sum of 2 quarters · filed 2023-11-07
$61.46M
10-Q · filed 2023-11-07
$80.67M
derived: sum of 4 quarters · filed 2023-11-07
2022-06-30$22.94M
10-Q · filed 2023-08-03
$41.40M
10-Q · filed 2023-08-03
$60.62M
derived: sum of 3 quarters · filed 2023-08-03
$77.33M
derived: sum of 4 quarters · filed 2023-08-03
2022-03-31$18.46M
10-Q · filed 2023-05-04
$37.67M
derived: sum of 2 quarters · filed 2023-05-04
$54.38M
derived: sum of 3 quarters · filed 2023-05-04
$70.18M
derived: sum of 4 quarters · filed 2023-05-04
2021-12-31$19.21M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02
$35.92M
derived: sum of 2 quarters · filed 2023-03-02
$51.72M
derived: sum of 3 quarters · filed 2023-03-02
$65.50M
10-K · filed 2023-03-02
2021-09-30$16.71M
10-Q · filed 2022-11-09
$16.30M
10-Q · filed 2021-11-04
$32.51M
derived: sum of 2 quarters · filed 2022-11-09
$46.29M
10-Q · filed 2022-11-09
$45.06M
10-Q · filed 2021-11-04
$62.68M
derived: sum of 4 quarters · filed 2022-11-09
2021-06-30$15.80M
10-Q · filed 2022-08-04
$15.40M
10-Q · filed 2021-08-05
$29.58M
10-Q · filed 2022-08-04
$28.77M
10-Q · filed 2021-08-05
$45.97M
derived: sum of 3 quarters · filed 2022-08-04
$58.04M
derived: sum of 4 quarters · filed 2022-08-04
2021-03-31$13.78M
10-Q · filed 2022-05-05
$13.37M
10-Q · filed 2021-05-05
$30.17M
derived: sum of 2 quarters · filed 2022-05-05
$42.24M
derived: sum of 3 quarters · filed 2022-05-05
$52.70M
derived: sum of 4 quarters · filed 2022-05-05
2020-12-31$16.39M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03
$28.46M
derived: sum of 2 quarters · filed 2022-03-03
$38.92M
derived: sum of 3 quarters · filed 2022-03-03
$49.34M
10-K · filed 2022-03-03
$47.48M
10-K · filed 2021-03-04
2020-09-30$12.06M
10-Q · filed 2021-11-04
$22.53M
derived: sum of 2 quarters · filed 2021-11-04
$32.95M
10-Q · filed 2021-11-04
$45.36M
derived: sum of 4 quarters · filed 2021-11-04
2020-06-30$10.46M
10-Q · filed 2021-08-05
$20.88M
10-Q · filed 2021-08-05
$33.30M
derived: sum of 3 quarters · filed 2021-08-05
$51.03M
derived: sum of 4 quarters · filed 2021-08-05
2020-03-31$10.42M
10-Q · filed 2021-05-05
$22.83M
derived: sum of 2 quarters · filed 2021-05-05
$40.56M
derived: sum of 3 quarters · filed 2021-05-05
$53.30M
derived: sum of 4 quarters · filed 2021-05-05
2019-12-31$12.42M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04
$30.15M
derived: sum of 2 quarters · filed 2021-03-04
$42.89M
derived: sum of 3 quarters · filed 2021-03-04
$57.60M
10-K · filed 2021-03-04
2019-09-30$17.73M
10-Q · filed 2020-11-05
$30.47M
derived: sum of 2 quarters · filed 2020-11-05
$45.18M
10-Q · filed 2020-11-05
$56.25M
derived: sum of 4 quarters · filed 2020-11-05
2019-06-30$12.74M
10-Q · filed 2020-08-07
$27.45M
10-Q · filed 2020-08-07
$38.52M
derived: sum of 3 quarters · filed 2020-08-07
$55.08M
derived: sum of 4 quarters · filed 2020-08-07
2019-03-31$14.71M
10-Q · filed 2020-05-11
$25.77M
derived: sum of 2 quarters · filed 2020-05-11
$42.34M
derived: sum of 3 quarters · filed 2020-05-11
$58.70M
derived: sum of 4 quarters · filed 2020-05-11
2018-12-31$11.06M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05
$27.63M
derived: sum of 2 quarters · filed 2020-03-05
$43.98M
derived: sum of 3 quarters · filed 2020-03-05
$57.93M
10-K · filed 2020-03-05
2018-09-30$16.57M
10-Q · filed 2019-11-06
$32.92M
derived: sum of 2 quarters · filed 2019-11-06
$46.87M
10-Q · filed 2019-11-06
$64.69M
derived: sum of 4 quarters · filed 2019-11-06
2018-06-30$16.36M
10-Q · filed 2019-08-05
$30.30M
10-Q · filed 2019-08-05
$48.13M
derived: sum of 3 quarters · filed 2019-08-05
$63.66M
derived: sum of 4 quarters · filed 2019-08-05
2018-03-31$13.95M
10-Q · filed 2019-05-06
$31.77M
derived: sum of 2 quarters · filed 2019-05-06
$47.31M
derived: sum of 3 quarters · filed 2019-05-06
$62.75M
derived: sum of 4 quarters · filed 2019-05-06
2017-12-31$17.82M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07
$33.36M
derived: sum of 2 quarters · filed 2019-03-07
$48.80M
derived: sum of 3 quarters · filed 2019-03-07
$62.68M
10-K · filed 2019-03-07
2017-09-30$15.54M
10-Q · filed 2018-11-07
$30.98M
derived: sum of 2 quarters · filed 2018-11-07
$44.85M
10-Q · filed 2018-11-07
$62.01M
derived: sum of 4 quarters · filed 2018-11-07
2017-06-30$15.45M
10-Q · filed 2018-08-03
$29.32M
10-Q · filed 2018-08-03
$46.47M
derived: sum of 3 quarters · filed 2018-08-03
$62.21M
derived: sum of 4 quarters · filed 2018-08-03
2017-03-31$13.87M
10-Q · filed 2018-05-04
$31.03M
derived: sum of 2 quarters · filed 2018-05-04
$46.77M
derived: sum of 3 quarters · filed 2018-05-04
$61.98M
derived: sum of 4 quarters · filed 2018-05-04
2016-12-31$17.16M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16
$32.89M
derived: sum of 2 quarters · filed 2018-03-16
$48.11M
derived: sum of 3 quarters · filed 2018-03-16
$61.25M
10-K · filed 2018-03-16
2016-09-30$15.74M
10-Q · filed 2017-11-02
$30.95M
derived: sum of 2 quarters · filed 2017-11-02
$44.10M
10-Q · filed 2017-11-02
$59.00M
derived: sum of 4 quarters · filed 2018-03-16
2016-06-30$15.21M
10-Q · filed 2017-08-03
$28.36M
10-Q · filed 2017-08-03
$43.26M
derived: sum of 3 quarters · filed 2018-03-16
$59.62M
derived: sum of 4 quarters · filed 2018-03-16
2016-03-31$13.14M
10-Q · filed 2017-05-04
$28.05M
derived: sum of 2 quarters · filed 2018-03-16
$44.40M
derived: sum of 3 quarters · filed 2018-03-16
$54.09M
derived: sum of 4 quarters · filed 2018-03-16
2015-12-31$14.90M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16
$31.26M
derived: sum of 2 quarters · filed 2018-03-16
$40.95M
derived: sum of 3 quarters · filed 2018-03-16
$51.51M
10-K · filed 2018-03-16
2015-09-30$16.35M
10-Q · filed 2016-11-03
$26.04M
derived: sum of 2 quarters · filed 2016-11-03
$36.60M
10-Q · filed 2016-11-03
$48.50M
derived: sum of 4 quarters · filed 2017-03-22
2015-06-30$9.69M
10-Q · filed 2016-08-04
$20.25M
10-Q · filed 2016-08-04
$32.15M
derived: sum of 3 quarters · filed 2017-03-22
$41.46M
derived: sum of 4 quarters · filed 2017-03-22
2015-03-31$10.56M
10-Q · filed 2016-05-04
$22.46M
derived: sum of 2 quarters · filed 2017-03-22
$31.77M
derived: sum of 3 quarters · filed 2017-03-22
$41.07M
derived: sum of 4 quarters · filed 2017-03-22
2014-12-31$11.90M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-22
$21.21M
derived: sum of 2 quarters · filed 2017-03-22
$30.51M
derived: sum of 3 quarters · filed 2017-03-22
$38.71M
10-K · filed 2017-03-22
2014-09-30$9.31M
10-Q · filed 2015-11-05
$18.61M
derived: sum of 2 quarters · filed 2015-11-05
$26.81M
10-Q · filed 2015-11-05
$33.78M
derived: sum of 4 quarters · filed 2016-03-09
2014-06-30$9.30M
10-Q · filed 2015-08-07
$17.50M
10-Q · filed 2015-08-07
$24.47M
derived: sum of 3 quarters · filed 2016-03-09
$29.98M
derived: sum of 4 quarters · filed 2016-03-09
2014-03-31$8.20M
10-Q · filed 2015-05-06
$15.18M
derived: sum of 2 quarters · filed 2016-03-09
$20.68M
derived: sum of 3 quarters · filed 2016-03-09
$25.59M
derived: sum of 4 quarters · filed 2016-03-09
2013-12-31$6.97M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-09
$12.48M
derived: sum of 2 quarters · filed 2016-03-09
$17.39M
derived: sum of 3 quarters · filed 2016-03-09
$21.46M
10-K · filed 2016-03-09
$21.46M
6-K · filed 2014-03-06
2013-09-30$5.51M
10-Q · filed 2014-11-07
$10.42M
derived: sum of 2 quarters · filed 2014-11-07
$14.49M
10-Q · filed 2014-11-07
2013-06-30$4.91M
10-Q · filed 2014-08-14
$8.98M
10-Q · filed 2014-08-14
2013-03-31$4.07M
10-Q · filed 2014-05-14
2012-12-31$18.04M
10-K · filed 2015-03-13
$18.04M
6-K · filed 2014-03-06
2011-12-31$20.13M
10-K · filed 2014-03-28

Similar stocks

Stock NameCountryMarket CapPE Ratio
Kura Oncology, Inc. (KURA)United States$0.967B-3.29
Jade Biosciences, Inc. (JBIO)United States$0.936B-9.21
Corvus Pharmaceuticals, Inc. (CRVS)United States$0.994B-23.25
Janux Therapeutics, Inc. (JANX)United States$1.019B-9.15
Pacira BioSciences, Inc. (PCRX)United States$1.020B69.03
Apnimed, Inc. (APMD)United States$0.899B
MoonLake Immunotherapeutics (MLTX)Switzerland$1.031B-5.43
RIGEL PHARMACEUTICALS INC (RIGL)United States$0.893B2.25
Savara Inc (SVRA)United States$1.044B-9.10
Theravance Biopharma, Inc. (TBPH)$0.885B16.40